此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

NIO752在早期阿尔茨海默病参与者中的安全性、耐受性、药效学和药代动力学研究

2026年9月17日 更新者:Novartis Pharmaceuticals

一项随机、参与者和研究者设盲、安慰剂对照的研究,以评估单次鞘内给药 NIO752 降低早期阿尔茨海默病参与者脑脊液总 Tau 水平的能力

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

研究概览

详细说明

This is a phase 1b, randomized, double-blind, placebo-controlled study, in which 36 patients with early AD will be enrolled in one of three cohorts.

Cohorts 1 & 2 will receive a single intrathecal (IT) dose of NIO752 or placebo in the placebo-controlled part of the study, and multiple administrations of NIO752 in the open-label extension (OLE) part of the study.

Cohort 3 will receive two single IT doses of NIO752 or placebo in the placebo-controlled part of the study, and a single administration of NIO752 in the OLE part of the study.

Each cohort will enroll 12 participants, and they will be randomized into receiving NIO752 or placebo in 2:1 ratio. Participants in cohorts 1& 2 will remain in this study for approximately ~19 months, including ~18 in-clinic follow up visits during that period of time. In cohort 3, participants will remain in this study for a follow up period of approximately ~18 months including ~10 in-clinic follow up visits.

Cohorts will be enrolled sequentially.

Participants who complete the placebo-controlled part of the study will be eligible to continue in an OLE part of the study regardless of randomization assignment in the placebo-controlled part. All OLE participants will receive either two (cohorts 1 & 2) or one (cohort 3) dose of NIO752.

Study assessments will include physical and neurological examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), routine laboratory evaluation of CSF collected through lumbar puncture, adverse event, and serious adverse event monitoring. Cohort 3 participation will also require 3 MRI scans and 3 PET scans throughout the 18 months of the study.

研究类型

介入性

注册 (实际的)

38

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Lille、法国、59037
        • Novartis Investigative Site
      • Paris、法国、75013
        • Novartis Investigative Site
      • Toulouse、法国、31059
        • Novartis Investigative Site
      • Malmö、瑞典、221 85
        • Novartis Investigative Site
      • Stockholm、瑞典、141 86
        • Novartis Investigative Site
      • Kuopio、芬兰、70210
        • Novartis Investigative Site
      • Turku、芬兰、20520
        • Novartis Investigative Site
      • Barcelona、西班牙、08036
        • Novartis Investigative Site
      • Barcelona、西班牙、08041
        • Novartis Investigative Site
    • Valencia
      • Valencia、Valencia、西班牙、46017
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 74年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Main Inclusion Criteria (placebo-controlled part):

  • Between 30 to 74 years old (both inclusive) at the time of informed consent.
  • A diagnosis of mild Alzheimer's Disease (AD) or mild cognitive impairment (MCI) due to AD at screening with at least a 6-month decline in cognitive function prior to screening documented in the medical record. Both participants with sporadic AD as well as Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1) or Presenilin-2 (PSEN2) mutation carriers are eligible.
  • Participants must have a diagnosis of MCI due to AD or mild AD at screening as defined by a Clinical Dementia Rating Scale (CDR) Global Score of 0.5 or 1 and a Memory Score ≥ 0.5.
  • A history of CSF biomarkers supporting the diagnosis of AD obtained at any time point prior to screening, including CSF amyloid (amyloid-β 42 and/or 42/40 ratio) AND tau species (total tau and/or phosphorylated tau). All participants must have documented historical confirmation of both CSF biomarkers (amyloid-β and tau species) with results supporting a diagnosis of AD prior to screening. This criterion will be determined individually for each participant taking into consideration the biomarker assay used in each case. For participants (Cohorts 1 & 2 only) with no historical CSF biomarker information, a LP for CSF collection must be performed at the screening visit. For CSF collected at screening, participants must have confirmed positivity of amyloid-β-42 ≤ 1000 pg/mL as well as positivity on, at least, one of the following Tau biomarkers: phosphorylated-tau-181 > 12 pg/ml OR T-tau > 149.9 pg/mL as determined by the central laboratory.
  • Participant has a reliable study partner or caregiver (e.g., spouse, sibling, close friend, adult child) who, is at least 18 years old.
  • Participant resides in a proximity to the study site to allow a timely unscheduled visit to the study site, if necessary.
  • Participant is able to undergo lumbar puncture (LP), CSF collections, and blood draws, tolerate brain MRI and PET scanning, and able to participate and tolerate all study procedures at study visit.

Main Inclusion Criteria (OLE part):

  • Signed informed consent of protocol version inclusive of the OLE.
  • Participant must complete Day 170 of the placebo-controlled part of this study.

Main Exclusion Criteria (placebo-controlled part):

  • Participant lives in a skilled nursing facility or dementia care facility.
  • Any previous use of experimental therapy within 180 days or 5 half-lives prior to Day 1, whichever is greater. Previous exposure to anti-tau and anti-β-amyloid antibodies is allowed if at the time of screening at least 180 days have passed since the last dose. Previous exposure to amyloid vaccines or tau vaccines meant to treat AD, or previous treatment with oligonucleotides or with gene therapy at any time frame is not allowed.
  • Any current or past non-AD neurological conditions.
  • Other medical conditions including but not limited to poorly controlled diabetes mellitus, unstable angina, myocardial infarction, chronic heart failure, clinical significant conduction abnormalities, impaired renal or kidney function, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion or could interfere with the participation in or completion of the study.
  • Treatment with immunosuppressants, antipsychotics, lithium, neuroleptics, dopaminergic agonists, L-dopa, or monoamine oxidase inhibitors at the time of screening. Current use of medications, other than cholinesterase inhibitors and/or memantine, that could alter cognition, as determined by the Investigator. If the participant is receiving cholinesterase inhibitors and/or memantine, the dose must have been stable within 12 weeks prior to screening, and must remain stable during the duration of the study.
  • Brain MRI at screening or within 12 months prior to screening showing evidence of cerebrovascular disease such as acute or sub-acute micro- or macrohemorrhage, significant signs of major cerebrovascular disease, or any other imaging evidence that, in the opinion of the Investigator, makes the participant unsuitable for the study.

Main Exclusion Criteria (OLE part):

  • Use of any investigational drugs, or participation in a clinical trial with an investigational new drug (other than NIO752), after completing the initial placebo-controlled part of this trial
  • Participants who withdrew informed consent while participating in the main placebo-controlled part of the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:NIO752 - Dose A - Cohort 1

A single intrathecal injection of Dose A

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Multiple intrathecal injections of NIO752 of Dose A

Two intrathecal injections of NIO752 at dose C

Single intrathecal injection of NIO752 at dose C

安慰剂比较:Matching placebo - Cohort 1

A single intrathecal injection of artificial cerebrospinal fluid (CSF)

A single intrathecal injection of matching placebo

Two intrathecal injections of matching placebo

实验性的:NIO752 Dose B - Cohort 2

A single intrathecal injection of Dose B

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Multiple intrathecal injections of NIO752 of Dose A

Two intrathecal injections of NIO752 at dose C

Single intrathecal injection of NIO752 at dose C

安慰剂比较:Matching placebo - Cohort 2

A single intrathecal injection of artificial cerebrospinal fluid (CSF)

A single intrathecal injection of matching placebo

Two intrathecal injections of matching placebo

实验性的:NIO752 OLE - Cohorts 1 and 2

Multiple intrathecal injections of Dose A

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Multiple intrathecal injections of NIO752 of Dose A

Two intrathecal injections of NIO752 at dose C

Single intrathecal injection of NIO752 at dose C

实验性的:NIO752 - Dose C - Cohort 3

Two intrathecal injections of Dose C

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Multiple intrathecal injections of NIO752 of Dose A

Two intrathecal injections of NIO752 at dose C

Single intrathecal injection of NIO752 at dose C

安慰剂比较:Matching Placebo - Cohort 3

Two intrathecal injections of artificial cerebrospinal fluid (CSF)

A single intrathecal injection of matching placebo

Two intrathecal injections of matching placebo

实验性的:NIO752 OLE - Cohort 3

Single intrathecal injection of Dose C

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Multiple intrathecal injections of NIO752 of Dose A

Two intrathecal injections of NIO752 at dose C

Single intrathecal injection of NIO752 at dose C

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in cerebrospinal total tau from baseline to Day 85
大体时间:Baseline, Day 85

Total tau protein levels in cerebrospinal fluid. More frequent timepoints might be added as deemed necessary per the site Investigator's judgment.

Baseline, Day 85

次要结果测量

结果测量
措施说明
大体时间
Number of adverse events and serious adverse events
大体时间:Cohort 1 & 2: Baseline up to 170 days (placebo-controlled part) and up to 589 days (OLE part), Cohort 3: Baseline up to 169 days (placebo-controlled part) and up to 507 days (OLE part)

Adverse events are assessed at each clinic visit. Laboratory values and other safety assessment values considered clinically significant by the investigator and meet the definition of adverse event will be reported.

Cohort 1 & 2: Baseline up to 170 days (placebo-controlled part) and up to 589 days (OLE part), Cohort 3: Baseline up to 169 days (placebo-controlled part) and up to 507 days (OLE part)
Concentration of NIO752 in cerebrospinal fluid (CSF)
大体时间:Cohorts 1 & 2: Pre-dose, Days 57, 85, 170 (placebo-controlled part) and Days 252, 420, and 588 (OLE part), Cohort 3: Pre-dose, day 1, 57, 85, 169 (placebo-controlled part) and Days 388 and 506 (OLE part)

Concentration of NIO752 in CSF

Cohorts 1 & 2: Pre-dose, Days 57, 85, 170 (placebo-controlled part) and Days 252, 420, and 588 (OLE part), Cohort 3: Pre-dose, day 1, 57, 85, 169 (placebo-controlled part) and Days 388 and 506 (OLE part)
Cmax, Ctrough in plasma
大体时间:Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)

Maximum and trough level concentrations of NIO752 in plasma

Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)
Tmax in blood plasma
大体时间:Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)

Time of Cmax in plasma post-IT injection

Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)
AUC-last in blood plasma
大体时间:Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)

Area under curve (AUC) from time zero to the last measurable concentration sampling time (t-last) (mass x time x volume-1)

Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)
AUC-inf in blood plasma
大体时间:Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)

The AUC from time zero to infinity (mass x time x volume-1)

Cohorts 1, 2 & 3: Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post first dose. Cohort 1 & 2: Days 14, 57, 85 and 170 (pbo-controlled part) and 252, 253, 420, 421, and 588 (OLE) Cohort 3: Days 14, 57, 85 and 169 (pbo-controlled part) and 338 and 506 (OLE)
Change in CSF total Tau
大体时间:Cohorts 1 & 2: Pre-dose, Days 57, 85, 170 (placebo-controlled part) and Days 252, 420, and 588 (OLE part), Cohort 3: Pre-dose, day 1, 57, 85, 169 (placebo-controlled part) and Days 388 and 506 (OLE part)

Evaluating the ability of NIO752 to lower CSF total tau in participants with early AD when administered as multiple doses

Cohorts 1 & 2: Pre-dose, Days 57, 85, 170 (placebo-controlled part) and Days 252, 420, and 588 (OLE part), Cohort 3: Pre-dose, day 1, 57, 85, 169 (placebo-controlled part) and Days 388 and 506 (OLE part)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Madhav Thambisetty, MD PhD、Novartis Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年2月23日

初级完成 (实际的)

2026年7月30日

研究完成 (估计的)

2027年9月24日

研究注册日期

首次提交

2022年7月11日

首先提交符合 QC 标准的

2022年7月19日

首次发布 (实际的)

2022年7月21日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅